SynKIR-110 is under clinical development by Verismo Therapeutics and currently in Phase I for Bile Duct Cancer (Cholangiocarcinoma). According to GlobalData, Phase I drugs for Bile Duct Cancer (Cholangiocarcinoma) have an 87% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SynKIR-110’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
SynKIR-110 is under development for the treatment of cholangiocarcinoma, ovarian cancer, malignant pleural mesothelioma, peritoneal cancer and fallopian tube cancer. The drug candidate comprises of T cells genetically modified to express killer immunoglobulin-like receptors (KIRs) and DAP12 protein that deliver important signals to T cells that promote T cell proliferation. It acts by targeting cells expressing mesothelin. It is administered through intravenous drip route. The drug candidate is being developed based on KIR-CAR platform. It was under development for the treatment of pancreatic cancer.
Verismo Therapeutics overview
Verismo Therapeutics, Inc., is a pharmaceutical company develops novel chimeric antigen receptors (CARs) that enhance T-cell-based cellular immunotherapy for cancer. The company is headquartered United States.
For a complete picture of SynKIR-110’s drug-specific PTSR and LoA scores, buy the report here.